OXALIPLATIN, Bemarituzumab, Placebo for AMG 552, FLUOROURACIL, FOLINIC ACID
20210096
Phase 3 small_molecule active
Quick answer
OXALIPLATIN, Bemarituzumab, Placebo for AMG 552, FLUOROURACIL, FOLINIC ACID for Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active